We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+34.92%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$237M
Cap. Flow
+$422M
Cap. Flow %
39.55%
Top 10 Hldgs %
35.09%
Holding
191
New
51
Increased
37
Reduced
12
Closed
55

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.6M
2
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$16.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.7M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$6.77M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$10.1M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.16M
3
SLRN
ACELYRIN
SLRN
+$7.92M
4
PCVX icon
Vaxcyte
PCVX
+$7.26M
5
GPCR icon
Structure Therapeutics
GPCR
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FHTX icon
151
Foghorn Therapeutics
FHTX
$266M
– –
-15,292
Closed -$76.5K
IDYA icon
152
IDEAYA Biosciences
IDYA
$3.42B
– –
-216,949
Closed -$5.85M
IMUX icon
153
Immunic
IMUX
$190M
– –
-45,000
Closed -$551K
INSM icon
154
Insmed
INSM
$21.4B
– –
-154,900
Closed -$4.02M
IRON icon
155
CALL
Disc Medicine
IRON
$2.96B
– –
-284
Closed -$1.33M
IRON icon
156
PUT
Disc Medicine
IRON
$2.96B
– –
-1,526
Closed -$7.17M
ITOS
157
CALL
DELISTED
iTeos Therapeutics
ITOS
– –
-3,056
Closed -$3.35M
JSPR icon
158
Jasper Therapeutics
JSPR
$21M
– –
-112,509
Closed -$788K
KALV
159
DELISTED
KalVista Pharmaceuticals
KALV
– –
-142,692
Closed -$1.37M
LLY icon
160
Eli Lilly
LLY
$1.02T
– –
-1,227
Closed -$716K
MREO
161
Mereo BioPharma
MREO
$54.7M
– –
-591,676
Closed -$191K
MRSN
162
DELISTED
Mersana Therapeutics
MRSN
– –
-63,191
Closed -$2.01M
OCUL icon
163
Ocular Therapeutix
OCUL
$1.79B
– –
-21,590
Closed -$67.8K
PCVX icon
164
Vaxcyte
PCVX
$7.81B
– –
-142,417
Closed -$7.26M
PTCT icon
165
PTC Therapeutics
PTCT
$5.68B
– –
-10,862
Closed -$243K
QQQ icon
166
PUT
Invesco QQQ Trust
QQQ
$453B
– –
-1,200
Closed -$43M
RARE icon
167
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-174,945
Closed -$6.24M
RCUS icon
168
Arcus Biosciences
RCUS
$3.55B
– –
-254,876
Closed -$4.07M
REPL icon
169
CALL
Replimune Group
REPL
$941M
– –
-2,325
Closed -$3.98M
REPL icon
170
PUT
Replimune Group
REPL
$941M
– –
-5,438
Closed -$9.3M
RVMD icon
171
PUT
Revolution Medicines
RVMD
$39.9B
– –
-2,035
Closed -$5.63M
RVPH
172
CALL
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-255
Closed -$2.49M
SCPH
173
DELISTED
scPharmaceuticals
SCPH
– –
-18,647
Closed -$133K
SNDX icon
174
CALL
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-2,500
Closed -$3.63M
SNDX icon
175
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-4,000
Closed -$58.1K
4 5 6
7
8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Ikarian Capital held 191 positions worth $1.07B, up 28% from $831M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ikarian Capital deployed $422M of net new capital in Q4 2023, opening 51 new positions and adding to 37 existing holdings. Its largest new stake was argenx: 70,000 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 32% a quarter earlier.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $9.16M trimmed.

  • Ikarian Capital's largest Q4 2023 buy was argenx: 70,000 shares worth $26.5M.
  • Ikarian Capital added most to Disc Medicine in Q4 2023, an estimated $2.67M increase.
  • Ikarian Capital's biggest Q4 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $9.16M.
  • Ikarian Capital fully exited Akero Therapeutics in Q4 2023, selling an estimated $10.1M.
  • Ikarian Capital's ten largest holdings make up 35% of its $1.07B portfolio in Q4 2023.
  • Ikarian Capital opened 51 new positions and closed 55 in Q4 2023.
  • Ikarian Capital's portfolio value rose 28% quarter-over-quarter to $1.07B.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.